Stockreport

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. - Class A Ordinary Shares  (APLM) 
PDF Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class [Read more]